COPENHAGEN, April 27 Danish drugmaker Novo
Nordisk experienced strong competition in the insulin
market in the United States in the first quarter of the year.
"We have seen strong competition in the first quarter,"
Chief Financial Officer Jesper Brandgaard said in a webcast
after the company published first-quarter results.
Novo Nordisk's main competitors insulin are Eli Lilly
Brandgaard said he expected the company's insulin market
share to improve in the United States going forward.
Novo Nordisk, the world's biggest insulin producer, nudged
up its full-year 2012 outlook after first-quarter operating
profit rose 18 percent.
(Reporting by Copenhagen Newsroom)